fda warning letters glp-1 september 2025 news issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Warns Telehealth Firms Over
Description
In the United Kingdom, a large private market has developed ahead of NHS access, with rationing shaping who gets treated on public funding
Why it matters: Microdoses of GLP-1s are not FDA approved, but the ad hoc practice of smaller doses began taking off on social media last year
Teotia emphasizes that this procedure restores contour
Shift to Clinical Data: Confounding factors like age, comorbidities, and disease severity with GLP-1 administration did not provide clear conclusions
These medications include semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)
